Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]

Invitation to participate

• Final stakeholder list (PDF 92 KB)

  Published:

  12 May 2025

• Equality impact assessment (scoping) (PDF 114 KB)

  Published:

  12 May 2025

• NICE's response to comments on the draft scope and provisional stakeholder list (PDF 113 KB)

  Published:

  12 May 2025

• Final scope (PDF 54 KB)

  Published:

  20 May 2025